145 related articles for article (PubMed ID: 7531332)
1. Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose.
Kawa S; Tokoo M; Oguchi H; Furuta S; Homma T; Hasegawa Y; Ogata H; Sakata K
Pancreas; 1994 Nov; 9(6):692-7. PubMed ID: 7531332
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.
Kawa S; Oguchi H; Kobayashi T; Tokoo M; Furuta S; Kanai M; Homma T
Br J Cancer; 1991 Nov; 64(5):899-902. PubMed ID: 1931612
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2.
Kawa S; Kato M; Oguchi H; Hsue GL; Kobayashi T; Koiwai T; Tokoo M; Furuta S; Ichikawa T; Kanai M
Scand J Gastroenterol; 1992 Aug; 27(8):635-43. PubMed ID: 1359630
[TBL] [Abstract][Full Text] [Related]
5. Preparation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2.
Kawa S; Kato M; Oguchi H; Kobayashi T; Furuta S; Kanai M
Scand J Gastroenterol; 1991 Sep; 26(9):981-92. PubMed ID: 1682994
[TBL] [Abstract][Full Text] [Related]
6. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.
Satake K; Takeuchi T
Pancreas; 1994 Nov; 9(6):720-4. PubMed ID: 7846015
[TBL] [Abstract][Full Text] [Related]
7. Role of tumour markers, cytogenetics.
Lamerz R
Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809
[TBL] [Abstract][Full Text] [Related]
8. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers.
Miyahara S; Takahashi H; Akita H; Sasaki K; Mukai Y; Iwagami Y; Hasegawa S; Yamada D; Tomimaru Y; Noda T; Wada H; Kobayashi S; Doki Y; Eguchi H
Ann Surg Oncol; 2024 May; 31(5):2932-2942. PubMed ID: 38368291
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Levels in Patients with Pancreatic Cancer.
Shimizu Y; Sugiura T; Ashida R; Ohgi K; Yamada M; Otsuka S; Uesaka K
Ann Surg Oncol; 2023 Sep; 30(9):5792-5800. PubMed ID: 37248377
[TBL] [Abstract][Full Text] [Related]
12. ASO Author Reflections: Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Values in Patients with Pancreatic Cancer: Focusing on the Usefulness in Patients with Normal CA19-9.
Shimizu Y; Sugiura T; Ashida R; Ohgi K; Yamada M; Otsuka S; Uesaka K
Ann Surg Oncol; 2023 Sep; 30(9):5801-5802. PubMed ID: 37355518
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy.
Tsutsumi K; Kawamoto H; Hirao K; Sakakihara I; Yamamoto N; Noma Y; Fujii M; Kato H; Ogawa T; Ishida E; Kuwaki K; Nouso K; Okada H; Yamamoto K
Pancreatology; 2012; 12(5):409-16. PubMed ID: 23127528
[TBL] [Abstract][Full Text] [Related]
14. [Molecular size heterogeneity of SPan-1 antigen and co-expression with Lewis phenotype determinants in sera from gastrointestinal malignant diseases].
Chung YS; Yamashita Y; Sawada T; Kondo Y; Kim K; Inui M; Onoda N; Kubo T; Nakata B; Sowa M
Nihon Shokakibyo Gakkai Zasshi; 1992 Jul; 89(7):1442-9. PubMed ID: 1380997
[TBL] [Abstract][Full Text] [Related]
15. Serological and immunohistochemical studies on sialylated carbohydrate antigens in colorectal carcinoma.
Nakagoe T; Kusano H; Hirota M; Fukushima K; Hiratani K; Hara K; Tomita M
Gastroenterol Jpn; 1991 Jun; 26(3):303-11. PubMed ID: 1716232
[TBL] [Abstract][Full Text] [Related]
16. Expression of various sialylated carbohydrate antigens in malignant and nonmalignant pancreatic tissues.
Satomura Y; Sawabu N; Takemori Y; Ohta H; Watanabe H; Okai T; Watanabe K; Matsuno H; Konishi F
Pancreas; 1991 Jul; 6(4):448-58. PubMed ID: 1678888
[TBL] [Abstract][Full Text] [Related]
17. Loss of Lewis antigen expression on erythrocytes in some cancer patients with high serum CA19-9 levels.
Hirano K; Kawa S; Oguchi H; Kobayashi T; Yonekura H; Ogata H; Homma T
J Natl Cancer Inst; 1987 Dec; 79(6):1261-8. PubMed ID: 2447318
[TBL] [Abstract][Full Text] [Related]
18. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.
Luo G; Fan Z; Cheng H; Jin K; Guo M; Lu Y; Yang C; Fan K; Huang Q; Long J; Liu L; Xu J; Lu R; Ni Q; Warshaw AL; Liu C; Yu X
Pancreatology; 2018 Dec; 18(8):971-976. PubMed ID: 30131287
[TBL] [Abstract][Full Text] [Related]
19. Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A.
Tang H; Singh S; Partyka K; Kletter D; Hsueh P; Yadav J; Ensink E; Bern M; Hostetter G; Hartman D; Huang Y; Brand RE; Haab BB
Mol Cell Proteomics; 2015 May; 14(5):1323-33. PubMed ID: 25733690
[TBL] [Abstract][Full Text] [Related]
20. Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells.
Zhang K; Baeckström D; Brevinge H; Hansson GC
J Cell Biochem; 1996 Mar; 60(4):538-49. PubMed ID: 8707893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
